CN115942933A - 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物 - Google Patents

用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物 Download PDF

Info

Publication number
CN115942933A
CN115942933A CN202180051106.2A CN202180051106A CN115942933A CN 115942933 A CN115942933 A CN 115942933A CN 202180051106 A CN202180051106 A CN 202180051106A CN 115942933 A CN115942933 A CN 115942933A
Authority
CN
China
Prior art keywords
compound
asthma
treatment
use according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051106.2A
Other languages
English (en)
Chinese (zh)
Inventor
J•卡斯特罗-帕洛米诺拉里亚
J•卡马乔戈麦斯
N·卡斯特罗-帕洛米诺拉里亚
A·阿里萨阿尔瓦雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palobiofarma SL
Original Assignee
Palobiofarma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma SL filed Critical Palobiofarma SL
Publication of CN115942933A publication Critical patent/CN115942933A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN202180051106.2A 2020-08-21 2021-08-20 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物 Pending CN115942933A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382764.7 2020-08-21
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
CN115942933A true CN115942933A (zh) 2023-04-07

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051106.2A Pending CN115942933A (zh) 2020-08-21 2021-08-20 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物

Country Status (20)

Country Link
US (1) US20230321053A1 (https=)
EP (2) EP3957308A1 (https=)
JP (1) JP7794807B2 (https=)
KR (1) KR20230054444A (https=)
CN (1) CN115942933A (https=)
AU (1) AU2021327728A1 (https=)
BR (1) BR112023002778A2 (https=)
CA (1) CA3190081A1 (https=)
DK (1) DK4199922T3 (https=)
ES (1) ES3001104T3 (https=)
FI (1) FI4199922T3 (https=)
HR (1) HRP20241621T1 (https=)
HU (1) HUE069338T2 (https=)
LT (1) LT4199922T (https=)
MX (1) MX2023002156A (https=)
PL (1) PL4199922T3 (https=)
PT (1) PT4199922T (https=)
RS (1) RS66263B1 (https=)
SI (1) SI4199922T1 (https=)
WO (1) WO2022038261A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835766A (zh) * 2007-10-02 2010-09-15 帕罗生物制药有限公司 作为腺苷a1受体拮抗体的新化合物
CN107073114A (zh) * 2014-09-08 2017-08-18 赛福伦公司 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
CN110198939A (zh) * 2017-01-20 2019-09-03 帕罗生物制药有限公司 腺苷a3受体的调节剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219223A1 (en) 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
KR20160061352A (ko) 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835766A (zh) * 2007-10-02 2010-09-15 帕罗生物制药有限公司 作为腺苷a1受体拮抗体的新化合物
CN107073114A (zh) * 2014-09-08 2017-08-18 赛福伦公司 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
CN110198939A (zh) * 2017-01-20 2019-09-03 帕罗生物制药有限公司 腺苷a3受体的调节剂

Also Published As

Publication number Publication date
US20230321053A1 (en) 2023-10-12
EP3957308A1 (en) 2022-02-23
RS66263B1 (sr) 2024-12-31
JP2023538419A (ja) 2023-09-07
EP4199922B1 (en) 2024-09-25
DK4199922T3 (da) 2024-11-25
SI4199922T1 (sl) 2025-03-31
HRP20241621T1 (hr) 2025-01-31
KR20230054444A (ko) 2023-04-24
PT4199922T (pt) 2024-12-18
BR112023002778A2 (pt) 2023-03-14
LT4199922T (lt) 2025-01-10
AU2021327728A1 (en) 2023-03-09
JP7794807B2 (ja) 2026-01-06
CA3190081A1 (en) 2022-02-24
FI4199922T3 (fi) 2024-12-05
HUE069338T2 (hu) 2025-02-28
WO2022038261A1 (en) 2022-02-24
EP4199922A1 (en) 2023-06-28
MX2023002156A (es) 2023-03-01
ES3001104T3 (es) 2025-03-04
PL4199922T3 (pl) 2025-02-10

Similar Documents

Publication Publication Date Title
RU2766577C2 (ru) Способы лечения эозинофильного эзофагита
ES2645368T3 (es) Terapias para mejorar la función pulmonar
US10577414B2 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
CN116419746A (zh) 右旋普拉克索用于治疗中度至重度哮喘的用途
JP7794807B2 (ja) 気道疾患の治療に使用するための（１ｒ，３ｓ）－３－（（５－シアノ－４－フェニルチアゾール－２－イル）カルバモイル）シクロペンタン－１－カルボン酸およびその誘導体
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
CN116033900A (zh) 治疗冠状病毒暴露所致疾病的方法
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
US20230242652A1 (en) Treatments for atopic dermatitis
EA048711B1 (ru) (1r,3s)-3-((5-циано-4-фенилтиазол-2-ил)карбамоил)циклопентан-1-карбоновая кислота и ее производные для применения в лечении заболеваний дыхательных путей
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
TW202539683A (zh) 透過投予（ｒ）－２［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療中度至重度氣喘
HK40090654A (zh) 右旋普拉克索用於治疗中度至重度哮喘的用途
HK40114122A (zh) 用抗light抗体治疗哮喘的方法
HK40104675A (zh) 异位性皮肤炎的治疗
CN118488968A (zh) 用抗light抗体治疗哮喘的方法
HK1188603B (en) Therapies for improving pulmonary function
HK1188603A (en) Therapies for improving pulmonary function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination